Share Name Share Symbol Market Type Share ISIN Share Description
Diurnal Grp LSE:DNL London Ordinary Share GB00BDB6Q760 ORD GBP0.05
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 133.50p 131.00p 136.00p 133.50p 133.50p 133.50p 0 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -12.2 -18.0 - 69.70

Diurnal Grp Share Discussion Threads

Showing 1 to 5 of 25 messages
Chat Pages: 1
DateSubjectAuthorDiscuss
09/5/2017
07:48
Great post RA, as I have come to expect from you!
dusty_coplhopper
09/5/2017
04:21
A COMPELLING CASE… • Diurnal floated on AIM in December 2015 having raised £28.4 million (net of expenses) at 144 pence per Share. • The group is currently on track to become one the few, AIM-listed, UK biotech companies to successfully take a product from concept to commercialisation. • Specifically, Diurnal is on track to becoming a world leading specialty pharma company in endocrinology through its early, 2018 commercial launch of its flagship product Infacort®. • Infacort® is a novel hydrocortisone preparation designed for use in children suffering from adrenal insufficiency; a rare disease which affects 4,000 young children in Europe. There is currently no treatment option in Europe specifically designed to treat these patients. • EMA approval for Infacort® is expected in the short term. This should be transformative for the group as the approval will not only initiate substantial revenues in Q1 2018, but will also make Diurnal an attractive licensing partner for third parties focussed in the endocrinology space (who do not have European commercial operations). • Significant progress has, so far, been made in the European Phase III trial of Chronocort® in congenital adrenal hyperplasia (CAH). • The company is currently on track to commence pivotal clinical programmes for Infacort® and Chronocort® in the US during the next couple of months. • First patient dosed with novel oral testosterone therapy in study evaluating pharmacokinetics, safety and tolerability in male patients with hypogonadism. • According to the leading research firm McKinsey, the addressable market potential of Diurnal’s late-stage product candidates, including further indication extensions in cortisol deficiency, runs into the billions... • Diurnal's product candidates are protected by an extensive patent portfolio, benefitting from a number of granted patents in key jurisdictions, alongside strong protection through orphan drug designations. • The company recently strengthened its Board with the appointment of City heavyweight Richard Bungay as Chief Financial Officer. • Held-to-maturity financial assets, cash and cash equivalents at 31 December 2016 of £25.6m (31 Dec 2015: £33.1m). Thus, the company is sufficiently funded to its first revenues (in Q1 2018) and beyond. • The company boasts a star-studded shareholder base with the likes of Invesco (12.5%), Oceanwood Capital (6.7%), Finance Wales (22%), and Richard Ross (3%). • 92.4% of the 52,210,759 shares in issue are in private hands, leaving a tight ‘free float’. • Current DCF valuation models (across 6 brokerage firms) place Diurnal at a pre-revenue market cap of £139m (253p) – more than double its current market cap of £65m. • Thus, on all the above, and when you consider that the company’s incredible near-commercial pipeline is only valued at £40m (less £25m cash), the shares are profoundly undervalued. .
researchanalyst1
04/1/2016
11:34
The CAH prevalence numbers also appear anomalous particularly as it is more prevalent among African Americans...
mw8156
27/12/2015
15:49
How come there are 64000 AI sufferers in Europe but only 16000 in the US according to the listing particulars document?
mw8156
21/12/2015
12:06
Diurnal is a globally-focused specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases. The Company has identified a number of conditions within the field of endocrinology which it believes are not adequately treated at present and it aims to develop products to address these patient needs where there is either no licensed medicine or the current treatment does not provide sufficient benefit to patients. The Company has two products in late-stage clinical development targeting Adrenal diseases; Chronocort® to be used for the treatment of Congenital Adrenal Hyperplasia and Adrenal Insufficiency in Adults and Infacort® which is to be used for the same conditions in children. The Company's main country of operation is the UK. 52,210,759 ordinary shares of a nominal value of 5 pence Issue price: 144p CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION: Capital to be raised: c.£25.3 million Anticipated market capitalisation on Admission: c.£75.2 million PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION: 83%
gersemi
Chat Pages: 1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20170919 11:56:28